OptiNose is a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat and allergy specialists. Co.'s commercial product, XHANCE® (fluticasone propionate) nasal spray is a therapeutic utilizing its proprietary Exhalation Delivery System (EDS®) for the treatment of chronic rhinosinusitis with nasal polyps and. Co.'s solutions also include EDS, which enables the development of drug-device combination products intended for self-administration. Co. has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to provide drug deposition. The OPTN average annual return since 2017 is shown above.
The Average Annual Return on the OPTN average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OPTN average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OPTN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|